Categories
Business News

Recruiting Participants for Real-World Psilocybin Mushroom Study

After more than a year of collaboration with the Center for Psychedelic and Consciousness Research at Johns Hopkins Medicine, we’re thrilled to announce the launch of our groundbreaking Real-World Psilocybin Mushroom Study.

The Need For More Research

The Center at Johns Hopkins University has studied psilocybin and other psychedelics in the laboratory setting for decades, and brings academically sanctioned and internationally acclaimed rigor to this field of study. Johns Hopkins—recognized worldwide as one of the leaders in psychedelic research—in 2000 was the first to obtain regulatory approval in the United States to reinitiate research with psychedelics in healthy, psychedelic-native volunteers. 

Our study will bring to light critical data around how individuals use psilocybin for therapeutic, recreational, or medical purposes outside the lab. Ultimately, the results from this study are essential to expanding on existing research, educating the public, and informing common-sense practices and policies.

“Studies exist showing the benefits of psilocybin for depression, smoking cessation, and cancer-related distress in the lab, among other things. But because our research is ‘real-world’, allowing participants to enroll for any reason and participate in any setting, we will learn unprecedented new details about how individuals are choosing to use this substance. Through our time listening to the community we have heard anecdotes of people using psilocybin for depression, anxiety, post traumatic stress disorder, and chronic pain, among other conditions. We hope to grow our understanding with a large sample set.”

Del Jolly, co-founder and director of Unlimited Sciences

Study Details

By collecting data from more than 1,000 individuals, 18 years and older, who are already planning to use psilocybin, we aim to investigate variables such as demographics, lifestyle, mindset, and personality traits. Additionally, we want to know more about the characteristics of the experience itself such as dosage, ingestion method, intention, guidance, and setting–all of which could influence psilocybin’s short- and long-term effects. 

In order to make the study scientifically significant and advance psychedelic science, we need as many people as possible to participate.  If you are intending on having a psilocybin experience in the near future, are 18 years or older, and can read and write English fluently, we encourage you to participate. Please note, this study is designed for individuals who are planning to take psilocybin in a single-dose session and is not designed for a recurring microdosing regimen.

Participating in the study is simple. It will include up to 5 surveys over the course of three months and you can opt-out or reschedule at any time. Your first survey could take up to 40 minutes and each additional survey should take much less time. Your responses are held in a HIPPA compliant platform and none of your personally identifiable information will be shared with anyone outside of Johns Hopkins University study team and the results will be published anonymously. After 6 months, your email will also be deleted. 

Why Your Participation Matters

Participation in the study will contribute to the evolution of groundbreaking scientific knowledge about the real-world conditions and outcomes of psilocybin use. Additionally, we’re offering a range of discounts and promotions from a carefully selected and aligned group of partner companies. Read the press release here.

Categories
News

Unlimited Voices: Media, Public Perception, and Psychedelics

The the last Unlimited Voices: Media, Public Perception, and Psychedelics, we discussed how the media has shaped the public’s opinion of psychedelics in the past and how we can accurately represent psychedelics in the media moving forward.

To offer brilliant insights on this topic, we were joined by by film producer, musician and host of Gaia’s Psychedelica and Limitless, Ben Stewart; Producer of The Healing Powers and Media Director at Lucid News, Mareesa Stertz; and Emmy award winning journalist, Cyndi Lundeberg.

We had an impressive 88 registrants from all over the world including the: U.S., Germany, Canada, France, Austria, Portugal, Spain, and Jamaica.

One of our favorite moments from the webinar was a discussion on how psychedelics can break through to mainstream media. Our brilliant guests offered insights on how decriminalization, science, and social proof could positively impact the widespread social acceptance of psychedelics in the media. Check out that clip here.

If you missed our first webinar, you can catch the next Unlimited Voices: Decriminalizing Psychedelics on May 8th at 12:00 MDT where we’ll be celebrating the one year anniversary of the decriminalization of psilocybin in Denver. On this special edition, we’ll discuss how that campaign helped ignite a movement to decriminalize psychedelics across more than 100 cities nationwide and what the future holds for the movement at-large. 

We’re honored to be joined by some of the most prominent leaders of the decriminalization movement: the Co-Founder of Decriminalize Nature OaklandCarlos Plazola; Co-Founder and Executive Director of SPOREKevin Mathews; and Iowa State RepresentativeJeff Shipley.

To get notified about our upcoming webinars, sign up for our newsletter and follow us on Facebook, Instagram, LinkedIn and Twitter.

Categories
News

Unlimited Voices: Building Community Through Psychedelics

On April 10, we launched the first segment of our new LIVE webinar series, Unlimited Voices: real-world psychedelic conversations for everyone. By creating a platform where anyone can safely ask questions and get accurate answers from experts in psychedelic-related fields, we hope to cultivate a truly inclusive community.

The first Unlimited Voices: Building Community Through Psychedelics focused on the theme of “community” — ways that we can continue to build community and integrate lessons from plant medicine, in light of the challenges posed by the current pandemic. To offer expert insights on this subject, we were joined by co-founder of Thank You Plant Medicine, Jonathan Glazer, co-founder and director of Project New Day, Dr. Alli Feduccia, and Director of Marketing & Strategy for High Existence, Mike Slavin. In case you missed the webinar, check out the full recording.

Overall, we were thrilled to have over 137 registrants from countries all over the world including: Thailand, Canada, Bulgaria, United Kingdom, South Africa, Israel, Portugal, Romania, Spain, Netherlands, Nepal, Greece, and Jamaica.

One of our favorite moments from the webinar was when an attendee asked for advice about taking psychedelics during quarantine. Our panelists had some powerful words of wisdom about acknowledging your set, setting, state of mind and emotions before deciding to embark on a psychedelic experience always, but especially right now. Check out that clip on our Instagram feed.

Some of our attendees also asked about upcoming virtual retreat opportunities. On April 24-26, HighExistence is hosting Metamorphosis: a free 3-day “stay at home” retreat for empowerment, resilience, and meaning during these transformative times.You can learn more and claim your seat here.

If you missed our first webinar, you can catch the next Unlimited Voices: Media, Public Perception, and Psychedelics on April 30 at 12:00 MDT. We’ll discuss how the media has shaped the public’s opinion of psychedelics in the past and how we can accurately represent psychedelics in the media moving forward. To offer brilliant insights on this topic, we’re honored to be joined by by film producer, musician and host of Gaia’s Psychedelica, Ben Stewart; Producer of The Healing Powers and Media Director at Lucid News, Mareesa Stertz; and Emmy award winning journalist, Cyndi Lundeberg.

To get notified about our upcoming webinars, sign up for our newsletter and follow us on Facebook, Instagram, LinkedIn and Twitter.

Categories
News

Breast cancer, psychedelics, and end-of-life anxiety – a survivor’s story.

Breast cancer doesn’t discriminate–about 1 in 8 women in the U.S. will develop it over the course of her lifetime. In 2020, an estimated 276,480 new cases are expected to be diagnosed in women in the U.S. For women in the U.S., breast cancer death rates are higher than those for any other cancer, besides lung cancer–about 42,170 women in the U.S. will die from it this year.

Cancer, Depression and Anxiety

It is not just the disease that permanently alters the lives of women with breast cancer. The grueling treatment processes, medical expenses, the fear and anxiety of death and dying can compound. In fact, up to 40% of cancer patients often develop a chronic syndrome of psychosocial distress including depressed mood, anxiety and reduced quality of life. The impact that chronic depression and anxiety has on cancer patients cannot be understated. It often results in decreased treatment adherence, prolonged hospitalization and increased suicidality. Of course, traditional antidepressants and even benzodiazepines can be used to treat depressed mood and anxiety in cancer patients, but they are generally a short-term reprieve due to the side effects and the impact of the withdrawal period.

Johns Hopkins Study of Psilocybin in Cancer Patients

Over the past few years, there have been several promising interventions using classic hallucinogens, including psilocybin, to decrease depression and anxiety in cancer patients. In 2016, a landmark double-blind study conducted by Johns Hopkins University recruited 51 cancer patients with life-threatening diagnoses and symptoms of depression and anxiety to test the power of psilocybin. 

The researchers found that a substantial majority of people suffering cancer-related anxiety or depression experienced considerable relief for up to six months from a single large dose of psilocybin. 

  • Six months after the final session of treatment, about 80% of participants continued to show clinically significant decreases in depressed mood and anxiety. 
  • 83% percent reported increases in well-being or life satisfaction.
  • 67% of participants reported the experience as one of their top five meaningful experiences in their lives (among the birth of a first child and getting married).
  • 70% reported the experience as one of the top five spiritually significant lifetime events.

Ultimately, the study demonstrated that psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer. Deborah Servetnick was one of the participants in this study.

Deborah’s Story

Deborah Servetnick was diagnosed with stage three breast cancer in 2011. She felt desperate, depressed and lost. She grappled with thoughts about how her experience with cancer was justification that her life wasn’t too easy–she questioned her worthiness of living a good life. When Deborah was considering becoming a participant in the study, she recognized that although she had had a few psychedelic experiences when she was younger, she hadn’t experimented in decades. 

Once she began the psilocybin study, everything changed. She felt that she did deserve a life worth living and basked in the realization that everything is connected. As she states, “If I hadn’t gotten into this Johns Hopkins study, I can’t even imagine what my life would be like…it really saved my life.” While it took her years for her “chemo brain” to recover, she believes that her  recovery was due to psychedelics. In fact, as Deborah put it, “Almost all of the problems that I had during cancer were from prescription drugs. I encountered no side effects from psilocybin, except I felt so much better.”

Deborah’s story and the scientific data garnered from this Johns Hopkins study is a testament to the healing power of psychedelics, including psilocybin. And this is just the beginning–we have only scratched the surface of the unlimited potential of psychedelic research and science. As Deborah concluded, “Psilocybin has its own infinite intelligence and we’re meant to bring it into our lives.” 

Deborah lives in Baltimore with her husband and daughter and has become an advocate for psychedelic science. She currently resides on the leadership team of the Baltimore Psychedelic Society, is an activist with Decriminalize DC, and an integration coach helping others tune into a new way of living. Most importantly, Deborah is happy, healthy and cancer free!

What’s Your Psychedelic Story?

Have you had a life altering experience with psychedelics? We believe that both quantitative data and storytelling are essential to the evolution of psychedelic research. That’s why we’re compiling Psychedelic Diaries™, a collection of video narratives showcasing how psychedelics have transformed people’s lives. If you have a story to share, contact us.

Categories
News

Unlimited Sciences Featured on the Joe Rogan Experience MMA Show #90 with Rashad Evans

In yesterday’s episode of the Joe Rogan Experience Show #90, Joe interviews Rashad Evans, a retired mixed martial artist, UFC Light Heavyweight Champion, and 2019 inductee of the UFC Hall of Fame. Among other topics, Joe and Rashad discuss Rashad’s transformative experiences with psilocybin and 5MEO- DMT. 

Rashad mentions a profound experience or  “ego death” during a psilocybin trip and how it ultimately led to him becoming a vegan. He also mentions that during his experience with “the toad” 5-MeO-DMT, he became more “ego aware” and took inventory of why he says and does certain things—questioning his motives and intent. Overall, Rashad says that his experience with psychedelics has transformed the way he thinks, eats, and acts in positive and spiritual ways.

Rashad discusses the potential healing power of psychedelics for other fighters too. Psychedelics are showing promise for the treatment of neurological ailments such as    Chronic Traumatic Encephalopathy, better known as CTE. He states, “…I’ve seen fighters have those down moments and those down moments are the moments where it’s harder to come back from. I think those are the times where a psychedelic or something like that could put things in perspective and allow the fighter to see the why behind the reason they’re doing it and maybe create a new why.”  

During the discussion, Rashad also mentions his good friend, Del Jolly, one of the co-founders of Unlimited Sciences. Del and Rashad met when one of Rashad’s family members needed help understanding dosing for CBD. Del was able to help Rashad by connecting him to Realm of Caring, the fiscal sponsor and inspiration for Unlimited Sciences.

Which is why we’re honored to have Rashad as an ally and advocate. As Rashad mentioned, in March 2020, we will be releasing an IRB-approved study in collaboration with Johns Hopkins University, to learn more about the use of psilocybin in naturalistic settings. If you are intending on having a psilocybin experience in the near future, are 18 years or older, and can read and write English fluently, we welcome you to participate. 


If you or someone you know is interested in being notified about the release of the study and receive future updates from Unlimited Sciences, sign up for our newsletter. If you have any questions about how to get more involved or support our work, please contact us.

When asked by Rogan what was next for him Rashad responded “I just want to help people.” We couldn’t agree more.

Categories
News

The Unlimited Sciences Story: A Message From Our Founders

How We Started

In 2012, two mothers shared a hospice counselor. Their children both had severe seizure disorders and they were not expected to live into adulthood. Heather Jackson and Paige Figi shifted their focus to improving their children’s quality of life exploring cannabinoid (CBD) therapy. Both of their children improved. Jackson’s son experienced complete remission from his seizures. Paige’s daughter, Charlotte was the inspiration for what has become one of the largest CBD companies to date – Charlotte’s Web

To help other families, Jackson and Figi started the Realm of Caring Foundation in Colorado Springs. The primary focus of the Foundation was to study how families used cannabinoid therapy – in states where it was legal. From their study, they analyzed a wide variety of information, including what products participants use, how it affects their quality of life, and how their symptoms may have changed due to cannabis therapy.

Ultimately, they developed the world’s largest repository of real-world data on cannabis use. From their research findings and public presence, they were able to help change the public perception around cannabis in monumental ways. The Realm of Caring helped 22 states pass cannabis legislation in some form and collaborated with the world’s leading researchers on cannabinoids. Realm of Caring now serves over 65,000 families, has given over $500,000 back to families in need in the form of grants and leads educational programs for consumers, medical professionals, and the community about cannabinoid therapy. 

How We Found the Power of Psilocybin

Unfortunately, after nearly four years without seizures, Jackson’s son’s seizures returned (not uncommon with his severe syndrome) and she was devastated. When Zaki used to have a seizure she stayed calm, cool and collected, and attended to the task at-hand. Now, her heart would beat rapidly, she would sweat, and lose the ability to concentrate. Having faced 13 years of chronic stress and trauma, she needed to heal herself.

After researching “natural plants for healing trauma” she followed the internet crumbs to peer-reviewed articles about psilocybin (magic mushrooms). After careful research, she established the right set, setting, dosing and intention and embarked on a psilocybin therapy journey that would change her life forever. Inspired by her experience with psilocybin, she wanted to help advance the psychedelic therapy movement–fortunately she already had a successful formula from her experience at the Realm of Caring.

Unlimited Sciences: The Future of Psychedelic Research

Until very recently, there was a long silence in the field of psychedelic studies. Since the rebirth of this research, the potential for psilocybin as a natural alternative to pharmaceutical drugs has become more evident and cities around the country are voting to decriminalize psilocybin and other psychedelics. 

In January 2018, Jackson consulted with the effort to decriminalize psilocybin in Denver with Del Jolly, former business development manager at  Charlotte’s Web and David Champion, former Co-founder and CPO of Baker Technologies. Together, not only did they help make Denver the first US city to decriminalize psilocybin mushrooms, but they assembled a small group of thinkers, creators, and activists to form Unlimited Sciences.

In light of the recent rebirth of psychedelic sciences, we saw the need to collect scientific data and testimonials about how people use psychedelics in their lives. In late 2018, we founded Unlimited Sciences as a psychedelic research nonprofit that combines the power of data and lived experiences to serve the community, educate the public, and inform common-sense practices and policies. Harnessing our combined knowledge about data science and alternative medicines, our team believes that safe and sustainable psychedelic practices can help our society heal and live without limitations.

Real-World Psilocybin Mushroom Use Study

Since its inception, Unlimited Sciences has continued to raise funds and chose to forge a collaborative relationship with the Center for Psychedelic and Consciousness Research at Johns Hopkins Medicine – the first research center of its kind in the U.S. 

While the Center at Johns Hopkins has been studying the controlled use of psilocybin in labs, there is not enough research around how psilocybin is used in a naturalistic setting or how the experience that psilocybin invokes can be offered safely at scale. Our team acknowledged that in order to advance the cause, we needed to do this research ourselves. Since then, we’ve developed an IRB-approved study that will be conducted by scientists at Johns Hopkins University School of Medicine, in collaboration with Unlimited Sciences. 

The goal of the study is to learn more about the positive and/or negative outcomes of using psilocybin in naturalistic settings (meaning outside a research laboratory), and any potential factors that could affect those outcomes. By collecting data from individuals who are already planning to use psilocybin, we aim to investigate variables such as demographics, lifestyle, mindset, and personality traits. In addition, we want to know more about the characteristics of the experience itself such as dosage, ingestion method, intention, guidance, and setting–all of which could influence psilocybin’s short- and long-term effects. 

The study will be released in March 2020 and anyone who is intending on having a psilocybin experience in the near future, is 18 years old or older and can read and write English fluently is welcome to participate. While we are starting with psilocybin, we have plans for conducting future studies on other types of psychedelics. 

We’re On A Mission

Ultimately, we’re on a mission to pursue new kinds of psychedelic research in order to unlock the unlimited  potential of psychedelics. Armed with data and stories of how people use psychedelics, the scientific community can hopefully find alternative solutions to the widespread mental health epidemics plaguing our country and the world-at-large.

Fortunately, we’re not alone in this effort. As a nonprofit, we are aided by in-kind donations, grants, and people like you–people who understand that the most effective way of unlocking the power of plant medicine is through continued research and new scientific discoveries. 

Thank you for joining US on our mission.